Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| LVLU | Lulu's Fashion Lounge | $10.84 | $4.07 | 60.12% | 857.6K | $19M | $2.98$15.80 |
| BDSX | Biodesix | $7.52 | $2.06 | 37.65% | 45.4M | $43M | $3.44$26.00 |
| BEAM | Beam Therapeutics | $36.08 | $8.53 | 30.96% | 3.7M | $2.8B | $13.53$36.13 |
| SOGP | Sound Group | $14.80 | $3.10 | 26.50% | 2.3M | $39M | $1.12$35.04 |
| CLRB | Cellectar Biosciences | $3.81 | $0.73 | 23.70% | 590K | $13M | $2.45$20.59 |
| FBRX | Forte Biosciences | $29.36 | $5.48 | 22.93% | 227.6K | $299M | $4.90$31.27 |
| OSS | One Stop Systems | $9.85 | $1.78 | 22.06% | 2.5M | $198M | $1.85$9.95 |
| KC | Kingsoft Cloud | $13.41 | $2.39 | 21.68% | 2.9M | $3.3B | $9.12$22.26 |
| CRWG | Themes ETF Trust - Leverage Shares 2x Long Crwv Daily ETF | $4.08 | $0.72 | 21.43% | 14.3M | - | $2.42$19.63 |
| KBAB | KraneShares Trust - KraneShares 2x Long Baba Daily ETF | $18.00 | $3.06 | 20.45% | 46.2K | - | $11.85$41.12 |
Related Articles
Featured Article
A Motley Fool Potluck of Financial News and Insight
Motley Fool Staff|Dec 3, 2024
It's Motley Fool Money's annual Thanksgiving financial meal. We're serving up humble pie, talking about the topics we're skipping this year at the dinner table, and answering questions you've sent our way.
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
George Budwell, PhD|Jan 16, 2024
Analysts have high hopes for these three innovation companies in 2024.
Is Beam Therapeutics Stock a Buy Now?
Alex Carchidi|Nov 18, 2023
It has plenty of money, but it'll be facing plenty of competition, too.
Advertisement
After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy?
Alex Carchidi|Oct 31, 2023
Some of the strategic shifts proposed by management are for the better.
5 Reasons Beam Therapeutics Remains a Risky Stock
James Halley|Oct 30, 2023
Shares of the gene-editing biotech might not have hit rock bottom yet.
Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble?
Keith Speights|Oct 25, 2023
Beam Therapeutics' pipeline will look slimmer going forward.
Beam Therapeutics Stock: Bear vs. Bull
Alex Carchidi|Oct 21, 2023
This biotech has a few factors in its corner, but it also faces a difficult path.
1 Risky Biotech Stock to Consider Buying, and 1 to Avoid
Alex Carchidi|Oct 18, 2023
Both are in a race against time to commercialize a medicine before cash runs out.
2 Cathie Wood Stocks I'm Bullish On
George Budwell, PhD|Oct 5, 2023
These two next-gen biotechs could be outstanding buys for patient investors.
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
Cory Renauer|Oct 3, 2023
The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome.
